Patents by Inventor Laxman Eltepu
Laxman Eltepu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240042039Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: ApplicationFiled: March 31, 2023Publication date: February 8, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20230381319Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: February 16, 2023Publication date: November 30, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
-
Publication number: 20230383296Abstract: The disclosure includes antisense oligonucleotides (ASOs), including gapmer ASOs, and methods of making and using the same.Type: ApplicationFiled: March 16, 2023Publication date: November 30, 2023Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Laxman Eltepu, Saul Martinez Montero, Jin Hong
-
Publication number: 20230365970Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: July 28, 2023Publication date: November 16, 2023Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20230332153Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: November 29, 2022Publication date: October 19, 2023Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20230242567Abstract: Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar bonded to a nucleobase and to a stereochemically enriched phosphoramidite as well as methods of their use and methods of making them.Type: ApplicationFiled: January 9, 2023Publication date: August 3, 2023Inventors: Sukumar SAKAMURI, Curt W. BRADSHAW, Dingguo LIU, Laxman ELTEPU
-
Patent number: 11712476Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: June 24, 2021Date of Patent: August 1, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Mancharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20230159929Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.Type: ApplicationFiled: September 7, 2022Publication date: May 25, 2023Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Patent number: 11597744Abstract: Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB).Type: GrantFiled: July 2, 2018Date of Patent: March 7, 2023Assignee: SIRIUS THERAPEUTICS, INC.Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Dingguo Liu, Laxman Eltepu
-
Patent number: 11549110Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: GrantFiled: February 15, 2022Date of Patent: January 10, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20220364096Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: March 5, 2021Publication date: November 17, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20220177888Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: February 15, 2022Publication date: June 9, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20220056069Abstract: Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.Type: ApplicationFiled: August 30, 2021Publication date: February 24, 2022Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Son Lam, Joseph Stock, Edward Hyungsuk Ha, Laxman Eltepu, Dingguo Liu, Bin Liu, Giuseppe Dello Iacono, Bryan R. Meade, Ayman Kabakibi
-
Publication number: 20220023427Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: ApplicationFiled: June 24, 2021Publication date: January 27, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Patent number: 11203611Abstract: Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.Type: GrantFiled: April 13, 2018Date of Patent: December 21, 2021Assignee: TOLLNINE, INC.Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Son Lam, Joseph Stock, Edward Hyungsuk Ha, Laxman Eltepu, Dingguo Liu, Bin Liu, Giuseppe Dello Iacono, Bryan R. Meade, Ayman Kabakibi
-
Patent number: 11077197Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure XXXIII, wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: June 8, 2017Date of Patent: August 3, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20210162053Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: October 7, 2020Publication date: June 3, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
-
Publication number: 20200392498Abstract: The invention features a hybridized polynucleotide construct containing a passenger strand, a guide strand loadable into a RISC complex, and (i) a 3?-terminal or an internucleotide non-bioreversible group in the guide strand; or (ii) a 5?-terminal, a 3?-terminal, or an internucleotide non-bioreversible group in the passenger strand, and a 5?-terminal, a 3?-terminal, or an internucleotide disulfide bioreversible group in the guide strand or the passenger strand. The invention also features methods of delivering a polynucleotide to a cell using the hybridized polynucleotide construct. The invention further features methods of reducing the expression of a polypeptide in a cell using the hybridized polynucleotide construct.Type: ApplicationFiled: February 3, 2020Publication date: December 17, 2020Inventors: Curt W. BRADSHAW, Sukumar SAKAMURI, Laxman ELTEPU, Son LAM, Dingguo LIU, Bryan MEADE, Giuseppe Dello IACONO, Joseph STOCK, Bin LIU
-
Patent number: 10835612Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: GrantFiled: August 8, 2017Date of Patent: November 17, 2020Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Jayaprakash K. Nair, Muthusamy Jayaraman, Laxman Eltepu
-
Patent number: 10821186Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: GrantFiled: September 6, 2018Date of Patent: November 3, 2020Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu